SELLAS Life Sciences Group, Inc. Debt Instrument, Fair Value Disclosure
SELLAS Life Sciences Group, Inc. (SLS) had Debt Instrument, Fair Value Disclosure of $6.90 million as of 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2019-03-22
- 2018-06-30: Debt Instrument, Fair Value Disclosure $6.90M.
- 2018-03-31: Debt Instrument, Fair Value Disclosure $8.00M.
- 2017-12-31: Debt Instrument, Fair Value Disclosure $10.20M.
- 2017-09-30: Debt Instrument, Fair Value Disclosure $11.97M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2018-06-30 | $6.90M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $8.00M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $10.20M 10-K · filed 2019-03-22 |
| 2017-09-30 | $11.97M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $13.17M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $13.17M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $17.62M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |